Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights
Highlights
– PALACE‑2 (multi‑center phase 1/2) evaluated preoperative pembrolizumab added to standard chemoradiotherapy (PPCT) in 143 patients with histologically confirmed, locally advanced, resectable esophageal squamous cell carcinoma (ESCC).
– Among 125 patients who underwent esophagectomy, pathologic complete response (pCR) was 43.2% (54/125); during neoadjuvant therapy 75.7% (106/140) experienced grade ≥3 adverse events (AEs).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.